Testosterone Undecanoate
Testosterone esterified with undecanoate, given as a very long-acting injection or as an oral capsule. Reference entry for the calculators, not tracked for price.
Reference compound, not sold here. Profile for research context only.
Overview
Testosterone undecanoate is the undecanoate ester of testosterone: the parent hormone with a straight eleven-carbon chain on its 17β-hydroxyl — the longest of the common esters, sold both as a very-long-acting castor-oil injection and as an oral capsule. This is a reference entry, not a product the index tracks; no undecanoate listings or prices appear here. It exists so the parent page can name the long end of the ester spectrum and the one testosterone injection with a boxed warning. The US injectable is Aveed (Endo); outside the US the same castor-oil preparation is Nebido (Reandron in some markets). Oral undecanoate is a separate kinetic regime, covered below. All are prescription-only Schedule III and prohibited under WADA class S1. Nothing here is dosing or treatment advice.
Chemistry#
C30H48O3, 456.7 g/mol (per the Aveed and Jatenzo labels), CAS 5949-44-0, PubChem CID 65157; the Aveed label's chemical name is 17β-undecanoyloxy-4-androsten-3-one. The chain is undecanoate — straight, C11 — so only about 63% of the mass is testosterone (288.4/456.7, arithmetic from the two sourced weights), the lowest fraction of the four esters profiled. The long chain is what makes the depot empty over months.
Formulation#
Aveed: 750 mg in 3 mL (250 mg/mL) single-use amber vial in refined castor oil with benzyl benzoate; deep gluteal IM at week 0, week 4, then every 10 weeks, with 30 minutes of observation after each injection. NDA 022219, approved 2014-03-05. Nebido: 1000 mg in 4 mL in refined castor oil with 2000 mg benzyl benzoate, injected every 10 to 14 weeks per the SmPC; UK first authorisation 2004-10-20, current MAH Grünenthal. No subcutaneous undecanoate product is approved.
Oral undecanoate is a different product class with no depot. Jatenzo (Tolmar; originally Clarus): 158, 198 and 237 mg capsules, 237 mg twice daily with food to start, range 158–396 mg; NDA 206089, 2019-03-27. Tlando (Verity): 112.5 mg capsules, 225 mg twice daily with food; NDA 208088, 2022-03-28. Kyzatrex (Marius): 50, 150 and 200 mg capsules, 200 mg twice daily with food; NDA 213953, 2022-07-27.
History#
Oral undecanoate entered clinical use in the late 1970s after Nieschlag's 1975 plasma-androgen study. Chinese investigators converted it into an injectable in tea-seed oil, the preparation Zhang studied in Klinefelter men in 1998. Behre and co-workers, with Jenapharm collaborators, showed in 1999 that reformulating in castor oil lengthened the half-life to 33.9 days; that product became Nebido in 2004 and Aveed in 2014, and the oral capsules followed in 2019–2022.
How it works
The ester is inert until hydrolysed; what acts is testosterone, so mechanism — androgen-receptor agonism directly and via dihydrotestosterone, feedback suppression of pituitary LH and of spermatogenesis — is the parent's and is described on the testosterone profile.
Pharmacokinetics#
Every injectable figure is an apparent, absorption-limited (flip-flop) half-life governed by release from the oil depot, not the hour-scale elimination of testosterone. Behre 1999 (phase I: 1000 mg in tea-seed oil into both gluteal muscles of 7 hypogonadal men; 1000 mg in castor oil at 250 mg/mL into one muscle of 14 patients) found the castor-oil preparation had the longer half-life, 33.9 ± 4.9 versus 20.9 ± 6.0 days (mean ± SEM). Zhang 1998 (8 men with Klinefelter syndrome, 500 and 1000 mg of the tea-seed preparation) reported terminal half-lives of 18.3 ± 2.3 and 23.7 ± 2.7 days. Those two small studies supply the numeric entry — 33.9 days typical, 18.3 days low. The Aveed label states no half-life: it gives a median 7-day time to peak (range 4–42 days), steady state at the third injection at 14 weeks, a mean ester Cmax of 90.9 ng/dL on day 4, and ester nearly undetectable 42 days after injection. The Nebido SmPC's release-rate half-life of 90 ± 40 days comes from a kinetic model and is not the same quantity as Behre's terminal fit. Oral undecanoate has no depot; the Tlando label gives an elimination half-life of approximately 2 hours, while the Jatenzo and Kyzatrex labels state none.
Evidence
Every study below used testosterone undecanoate; the route is named. Male contraception (injectable): Gu 2009, 1,045 healthy fertile Chinese men given 500 mg monthly for 30 months — 9 pregnancies in 1,554.1 person-years, cumulative failure 1.1 per 100 men. Type 2 diabetes prevention (injectable): T4DM randomised 1,007 men aged 50–74 in a lifestyle programme to 1000 mg or placebo at baseline, 6 weeks and every 3 months for 2 years, reporting fewer type 2 diabetes diagnoses in the treated arm. Pivotal pharmacokinetics (injectable): Morgentaler 2008, 750 mg at 0, 4 and 14 weeks over 24 weeks, the basis of Aveed's 10-week interval. Klinefelter syndrome: Zhang 1998, proposing 6–8-week intervals for the tea-seed preparation. Metabolic syndrome (injectable): the double-blind Moscow study, 1000 mg (n=113) versus placebo (n=71) at 0, 6 and 18 weeks. Oral: Swerdloff 2020, the Jatenzo program. The outcome trials TRAVERSE and the Testosterone Trials used transdermal gel, not undecanoate.
Anecdotal reports community-reported
What people describe in forums, blogs and uncontrolled clinic write-ups — experiential and unverified, not clinical evidence and not medical advice.
- Stable levels on one shot a weekcommonly reported
Users who cruise on undecanoate report one weekly shot giving very stable levels, no post-injection pain, fewer estradiol- and DHT-related sides and easy travel, with some tripling the dose before a long trip. The common verdict is that it suits lifelong replacement but not cycles, because it takes months to stabilise, to dial in and to clear; a minority felt far better after switching back to enanthate.
- The 10–12-week clinic protocolcommonly reported
Users on 1,000 mg every 10–14 weeks under a doctor commonly describe a rollercoaster: a strong peak one to two weeks in, sometimes with a panic attack or a burst of acne, then fatigue, joint pain and low-testosterone symptoms from week six to nine, with troughs in the 200s–300s ng/dL. Those who got the interval shortened or moved to 500 mg monthly report it evened out; some say it took a year to stabilise.
- Injection volumecommonly reported
The 3–4 mL single injection is a frequent complaint: users call that much oil in one spot unpleasant, say the site stays swollen longer and needs more rotation, and some split the ampoule into 250 mg every two to three weeks instead. Others note it is the only injectable some health systems license, so patients are stuck with the big shot or must change doctor.
- Oral capsulesa sizeable minority
Users on prescription oral undecanoate at 200 mg twice daily report only modest rises in total testosterone unless blood is drawn a few hours after a dose, and most dislike needing a fatty meal twice a day; several switched to injections and report far higher levels and better results. Older 20 mg capsules taken every other day are dismissed as near-zero bioavailability that still suppresses natural production.
- Hard to adjust, hard to stopcommonly reported
The most repeated criticism is that with a half-life quoted anywhere from three weeks to 53 days, dose changes take months to show, a bad batch or side effect cannot be bailed out of, and anyone who may want to stop or manage hematocrit quickly is advised to avoid it. Frontloading is suggested by some to reach steady levels faster and dismissed by others as pointless.
Safety
Class risks — erythrocytosis, androgenic skin effects, gynecomastia, fluid retention, suppressed spermatogenesis, mood change, venous thromboembolism, and the abuse syndrome — are the parent's and are set out on the testosterone profile. What is specific to this ester is the injection itself. Aveed carries a boxed warning for serious pulmonary oil microembolism (POME) — urge to cough, dyspnea, throat tightening, chest pain, dizziness, syncope — and anaphylaxis, during or immediately after injection and possible after any dose including the first. The label requires 30 minutes of observation after each injection, and the product is available only through the AVEED REMS Program with certified prescribers and settings; Drugs@FDA records REMS supplements from 2016-12-09 through 2024-10-08. The Nebido SmPC carries the same two cautions. In Aveed's 84-week study of 153 men the most common adverse reactions were acne (5.2%), injection-site pain (4.6%) and PSA increase (4.6%). The oral products' boxed warning for blood-pressure increases is listed as removed in 07/2025. Prescription-only Schedule III; the safety score of 3 mirrors the parent's and would be lower for unlabeled or underground products.
Reported side effects
Reported in published literature and user reports. Not a complete list, and not medical advice.
- Class effects of testosterone — erythrocytosis, acne, gynecomastia, fluid retention, suppressed spermatogenesis, mood changes, venous thromboembolism (see the testosterone profile)
- Pulmonary oil microembolism (urge to cough, dyspnea, throat tightening, chest pain, dizziness, syncope) and anaphylaxis during or immediately after IM injection — Aveed boxed warning, REMS, 30-minute observation
- Aveed 84-week study (153 men) — acne 5.2%, injection-site pain 4.6%, PSA increased 4.6%
- Blood-pressure increases — oral TU products carried a boxed warning, removed 07/2025
- Hypersensitivity to the vehicle — refined castor oil and benzyl benzoate (injectables)
If severe or unexpected symptoms occur, contact a qualified medical professional. Peptides·Index does not provide medical advice.
Cautions discuss with a clinician
- Known or suspected carcinoma of the prostate, or breast carcinoma in men (Aveed label)
- Women — Aveed is not indicated for use in women; pregnancy risk of fetal virilisation (class)
- Serious cardiac, hepatic or renal disease — fluid retention and edema risk (class)
- Known hypersensitivity to testosterone undecanoate, refined castor oil or benzyl benzoate (Aveed label; Nebido SmPC)
- Uncontrolled hypertension — the oral TU labels advise against use (Jatenzo label)
- Oral anticoagulants (warfarin)Androgens increase sensitivity; the anticoagulant dose may need reduction (label)
- Insulin and other antidiabetic drugsAndrogens may lower blood glucose and reduce insulin requirements (label)
- Corticosteroids / ACTHConcurrent use may increase fluid retention; caution in cardiac, renal or hepatic disease (Aveed label)
- Thyroid function testsAndrogens lower thyroxine-binding globulin, reducing total T4 while free hormone stays normal (label)
Timeline commonly reported
- Day 4
Mean undecanoate (ester) concentration peaks at 90.9 ng/dL on day 4 after an Aveed injection per the label; the ester is nearly undetectable 42 days after injection.
- Day 7 (range 4–42)
Serum testosterone reaches its maximum after a median of 7 days, then slowly declines (Aveed label section 12.3).
- Week 14 (3rd injection)
Steady state is reached at the third injection, 14 weeks into the 0, 4, then every-10-weeks Aveed regimen (label).
- Weeks to months
Downstream effects (libido, mood, body composition, erythropoiesis, bone) follow the testosterone timeline, not the ester's — see the testosterone profile.
FAQ
Is testosterone undecanoate a peptide?
No. It is testosterone esterified with undecanoic acid — a straight eleven-carbon chain on the 17β-hydroxyl — giving C30H48O3, 456.7 g/mol; the Aveed label's chemical name is 17β-undecanoyloxy-4-androsten-3-one. It is a reference entry so the parent testosterone page can compare esters; the index does not track undecanoate products or prices.
What is the half-life of testosterone undecanoate?
It depends on the oil and the route. In Behre's 1999 phase I study the castor-oil preparation (the one in Aveed and Nebido) had an apparent half-life of 33.9 days versus 20.9 days in tea-seed oil; Zhang 1998 reported 18.3 and 23.7 days for 500 and 1000 mg of the tea-seed preparation in Klinefelter men. The Aveed label states no half-life at all — only a median 7-day peak and steady state at the third injection — so the 33.9-day figure is attributed to the paper, not the label. Oral TU behaves completely differently: the Tlando label gives about 2 hours.
Why does Nebido say 90 days when Behre says 34?
They are different quantities. The Nebido SmPC describes the depot's release rate as a half-life of 90 ± 40 days from a kinetic model; Behre 1999 fitted the terminal decline of serum testosterone, 33.9 days. Both are absorption-limited descriptions of the castor-oil depot, and neither is the elimination half-life of testosterone, which the same SmPC puts at about one hour after IV dosing in elderly men.
Why is Aveed given with a 30-minute wait?
Its boxed warning: serious pulmonary oil microembolism reactions (urge to cough, dyspnea, throat tightening, chest pain, dizziness, syncope) and anaphylaxis have occurred during or immediately after injection, including after the first dose. Patients are observed in the healthcare setting for 30 minutes after every injection, and the product is available only through the AVEED REMS Program in certified settings.
Are the oral capsules the same drug?
Same molecule, different kinetics and products. Jatenzo (2019), Tlando (2022) and Kyzatrex (2022) are liquid-filled undecanoate capsules taken twice daily with food; they have no depot, the Tlando label gives an elimination half-life of about 2 hours, and the boxed warning they carried was for blood-pressure increases — each label lists it as removed in 07/2025 — not Aveed's pulmonary oil microembolism warning.
Sources
Starting references for the library summary. These are not dosing instructions or medical advice.
For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.